The Spectrum of Cutaneous Adverse Events During Encorafenib and Binimetinib Treatment in B-Rapidly Accelerated Fibrosarcoma-Mutated Advanced Melanoma
November 2018
in “
Journal of the European Academy of Dermatology and Venereology
”
Studysummary In this study, encorafenib combined with binimetinib was well tolerated in melanoma patients, resulting in relatively few cutaneous adverse events compared to other BRAF and MEK inhibitors.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on onlinelibrary.wiley.com →